Our median duration of follow-up was shorter than prior literature analyzing outcomes in IDH1/2 mutant gliomas after surgical resection, although our median approached the recommended threshold for IDH1/2 mutant gliomas [16]. This evidence concerns the gene IDH1 and central nervous system cancer.